Why the study?
Does apoC-III inhibition reduce plasma triglyceride levels in patients with hypertriglyceridemia?
Does apoC-III inhibition reduce plasma triglyceride levels in patients with hypertriglyceridemia?
ApoC-III inhibition represents a promising therapeutic target for managing hypertriglyceridemia and reducing cardiovascular risk.
May support apoC-III inhibition for hypertriglyceridemia; leaves open need for outcome trials before practice change.
Hypertriglyceridemia is a common feature of many metabolic disorders and has been identified as risk factor for cardiovascular disease. ApoC-III is commonly associated with triglyceride rich lipoproteins and has been identified as a potent modulator of plasma TG levels. The purpose of this review is to provide background on apoC-III and its role in the regulation of plasma TG and lipoprotein metabolism and to highlight preclinical and genetic evidence supporting apoC-III as a central target in cardiovascular disease progression. Finally, recent results from clinical trials evaluating a second generation antisense oligonucleotide (ASO) inhibitor of apoC-III will be summarized and the potential impact such a drug could have in the treatment of hypertriglyceridemia and associated comorbidities will be highlighted.
No takes yet. Share an insight, caveat, or question.
Bell et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: